Global Transdermal Drug Delivery System Market to reach USD 8.4 billion by 2027. Global Transdermal Drug Delivery System Market is valued at approximately USD 6.2 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 4.5 % over the forecast period 2021-2027. Transdermal drug delivery systems, which transport medications through the skin for therapeutic purposes, are an alternative to oral intravascular, subcutaneous, and transmucosal routes. The market is anticipated to rise due to an increase in the elderly population and the number of people suffering from chronic diseases. For instance, according to Statista, In 2019, almost 17.9 million people died worldwide from cardiovascular illnesses of various forms and reached 18 million deaths by the year 2020. Moreover, several key players are taking strategic initiatives to expand their presence in the market. For instance,
In July 2018 : The China Food and Drug Administration has granted UCB (Belgium) an Import Drug License (IDL) for their transdermal rotigotine patch???NEUPRO (CFDA).
Similarly, In august 2018: Luye Pharma (China) has purchased world rights to the Apleek contraceptive transdermal patch from Bayer AG (Switzerland).

However, Drug Failure and Recalls of Transdermal Drug Delivery Systems may impede market growth over the forecast period of 2021-2027.

The regional analysis of the global Transdermal Drug Delivery System Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World (ROW). North America is the leading region across the world in terms of market share due to growing prevalence of targeted diseases (such as, cardiovascular diseases, chronic pain, and central nervous system conditions) in the region. Whereas Asia Pacific is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027, due to rising number of research activities associated to transdermal drug delivery systems across APAC.
Major market player included in this report are:

Hisamitsu Pharmaceutical
Mylan N.V.
Echo Therapeutics
Novartis AG
Johnson & Johnson
Boehringer Ingelheim GmbH
Bayer AG
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Acrux Limited

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:
Transdermal Patches
Transdermal Semisolids
By Applications:
Pain Management
Hormonal Applications
Central Nervous System Disorders
Cardiovascular Diseases
Other Applications
By End use:
Home Care Settings
Hospitals & Clinics
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2017, 2018-19
Base year - 2019-2020
Forecast period - 2021 to 2027.

Target Audience of the Global Transdermal Drug Delivery System Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors